Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and
have a poor prognosis. They are highly heterogeneous tumors consisting of different …

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with a
poor prognosis. Despite conventional treatments, including surgery, radiation, and …

Background Breast cancer is a complex disease with a highly immunosuppressive tumor
microenvironment, and has limited clinical response to immune checkpoint blockade (ICB) …

Among the different breast cancer subsets, triple-negative breast cancer (TNBC) has the
worst prognosis and limited options for targeted therapies. Immunotherapies are emerging …

Simple Summary Microbiota plays a fundamental role in the induction, training and function
of the human immune system. The interactions between microbiota and immune cells have …

Animal models are critical for the preclinical validation of cancer immunotherapies.
Unfortunately, mouse breast cancer models do not faithfully reproduce the molecular …

Breast cancer is the most prevalent non-skin cancer diagnosed in females and developing
novel therapeutic strategies to improve patient outcomes is crucial. The immune system …

Neoadjuvant chemotherapy (NACT) has become the standard of care for high‐risk breast
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …

Purpose The rise of female breast cancer has created a significant global public health issue
that requires effective solutions. Disulfidptosis, a recently identified form of cell death …

Breast cancer (BC) is a lethal malignancy with high morbidity and mortality but lacks
effective treatments thus far. Despite the introduction of immune checkpoint inhibitors …